<DOC>
	<DOCNO>NCT00915278</DOCNO>
	<brief_summary>Dose find study MoaB PF-04605412 direct alpha5beta1 integrin . Main objective define MTD ( maximum tolerate dose ) MAD ( maximum administrable dose ) cancer patient pre treat unresponsive standard therapy .</brief_summary>
	<brief_title>A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm advanced measurable evaluable solid tumor unresponsive currently available therapy , curative therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy than12 week Adequate bone marrow , liver renal function Known brain metastasis Chemotherapy , radiotherapy , investigational cancer therapy within 4 week start screen procedure Major surgical procedure within 4 week start screen procedure Active bleed disorder , include gastrointestinal bleeding , evidence hematemesis , significant hemoptysis melena past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>PF-04605412</keyword>
	<keyword>advanced metastatic solid tumor</keyword>
</DOC>